Alicaforsen ( DrugBank: Alicaforsen )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	2
97	潰瘍性大腸炎	2

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00048295 (ClinicalTrials.gov)	May 2002	29/10/2002	Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease	ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s Disease	Crohn's Disease	Drug: Alicaforsen	Isis Pharmaceuticals	NULL	Active, not recruiting	12 Years	N/A	Both	150	Phase 3	Belgium;Czech Republic;Germany;Italy;Poland;Spain
2	NCT00048113 (ClinicalTrials.gov)	September 2001	24/10/2002	Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease	ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease	Crohn's Disease	Drug: Alicaforsen	Isis Pharmaceuticals	NULL	Completed	12 Years	N/A	Both	150	Phase 3	United States;Canada

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00063414 (ClinicalTrials.gov)	September 2003	25/6/2003	ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis	ISIS 2302-CS22, Phase II, Double-Blinded, Active-Controlled Study of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis (Left-Sided Colitis or Pancolitis With Left Sided Disease Flare)	Ulcerative Colitis	Drug: Alicaforsen	Isis Pharmaceuticals	NULL	Completed	18 Years	N/A	Both		Phase 2	United States
2	NCT00063830 (ClinicalTrials.gov)	June 2003	7/7/2003	ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.	ISIS 2302-CS27, Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis	Ulcerative Colitis	Drug: Alicaforsen	Isis Pharmaceuticals	NULL	Completed	18 Years	N/A	Both		Phase 2	United States